Objective:

To evaluate the effects of statin therapy on all-cause mortality and major cardiovascular disease in adults with type 2 diabetes, particularly focusing on low-risk groups.

Key Findings:

• Statin initiation was associated with lower risks of all-cause mortality and major cardiovascular disease across all risk categories, with risk ratios of 0.80 for all-cause mortality and 0.78 for major CVD in the lowest-risk group.
• In the lowest-risk group (<10% 10-year risk), statin therapy resulted in a 10-year absolute risk reduction of 0.53 percentage points for all-cause mortality and 0.83 percentage points for major CVD.
• Higher baseline risk correlated with increased absolute risk reductions, reaching 4.30 percentage points for all-cause mortality and 4.57 for major CVD in patients with ≥30% risk.

Interpretation:

Statins may provide significant benefits for primary prevention in adults with type 2 diabetes, even in those with low short-term cardiovascular risk, suggesting a reevaluation of treatment thresholds and the need for personalized clinical decision-making.

Limitations:

• Residual confounding due to observational design, particularly from unmeasured lifestyle factors.
• Potential misclassification of outcomes in primary care records.
• Study population predominantly White, limiting generalizability to diverse populations.

Conclusion:

Clinicians should consider statin therapy for all adults with type 2 diabetes, regardless of short-term cardiovascular risk, as benefits may extend beyond traditional risk thresholds, emphasizing the need for individualized treatment approaches.